Cinven to purchase Amdipharm
Cinven, a private equity group, announced today that it is to buy Amdipharm for 367 million pounds. Amdipharm is a family-owned niche pharmaceutical company.
The intention is to merge Amdipharm with Mercury Pharma, which Cinven bought earlier this year for 465 million pounds. This is part of Cinven’s plan to create a much larger producer of generic drugs.
“We absolutely want to buy more products from the larger pharmaceutical companies that are looking to tidy up their portfolios…I certainly could see an end business which is more than twice the size of what it is today.”
Cinven deal partner Supraj Rajagopalan in a telephone interview with Reuters.
The purchase is Cinven’s 14th acquisition in the healthcare sector.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.